Table 2. The Effect Of Study Medication On HRV (SDANN, TI, RMSSD) And QT Dispersion From Baseline And Between Drugs, Using Parametric And Non-Parametric Analyses.
| Parameters | Mean difference ± SEM | 95% CI | p-value | p-value |
| SDANN | ||||
| Baseline – losartan | –27 ± 8.3 | (–46, –7) | 0.014 | 0.012 |
| Baseline – (spiro + ACEI) | –31 ± 7.6 | (–49, –13) | 0.004 | 0.012 |
| Baseline – (losartan + spiro) | –39 ± 9.7 | (–62, –15) | 0.005 | 0.012 |
| Losartan – (spiro + ACEI) | –4 ± 9.7 | (–27, 18) | 0.65 | 0.4 |
| Losartan – (losartan + spiro) | –12 ± 10.8 | (–37,13) | 0.32 | 0.6 |
| (Spiro + ACEI) – (losartan + spiro) | –7 ± 10.4 | (–32,17) | 0.49 | 0.48 |
| Triangular index | ||||
| Baseline – losartan | –6 ± 2.1 | (–1, –1.6) | 0.016 | 0.018 |
| Baseline – (spiro + ACEI) | –8 ± 2.9 | (–15, –1.5) | 0.024 | 0.012 |
| Baseline – (losartan + spiro) | –8 ± 3 | (–14, –0.7) | 0.034 | 0.043 |
| Losartan – (spiro + ACEI) | –1.7 ± 4.1 | (–11, 8) | 0.68 | 0.77 |
| Losartan – (losartan + spiro) | –1.1 ± 1.9 | (–5, 3) | 0.58 | 0.57 |
| (Spiro + ACEI) – (losartan + spiro) | –0.6 ± 4.3 | (–9, 10) | 0.88 | 0.61 |
| rMSSD | ||||
| Baseline – losartan | –2.8 ± 1.3 | (–6, 0.4) | 0.078 | 0.046 |
| Baseline – (spiro + ACEI) | –5.7 ± 7.1 | (–11, 0.2) | 0.056 | 0.027 |
| Baseline – (losartan + spiro) | –6 ± 1.6 | (–9.8, -2.1) | 0.008 | 0.027 |
| Losartan – (spiro + ACEI) | –2.8 ± 2.6 | (–9, 3.4) | 0.31 | 0.29 |
| Losartan – (losartan + spiro) | –3.1 ± 1.3 | (–6, 0.04) | 0.053 | 0.027 |
| (Spiro + ACEI) – (losartan + spiro) | –0.25 ± 2 | (–5, 4.5) | 0.9 | 0.89 |
| QTc dispersion | ||||
| Baseline – losartan | 18 ± 3.3 | (10, 27) | 0.001 | 0.018 |
| Baseline – (spiro + ACEI) | 20 ± 3.3 | (12, 29) | 0.001 | 0.018 |
| Baseline – (losartan + spiro) | 27 ± 2.8 | (20, 34) | 0.0001 | 0.018 |
| Losartan – (spiro + ACEI) | 1.9 ± 1.3 | (–1.3, 5.2) | 0.2 | 0.23 |
| Losartan – (losartan + spiro) | 8 ± 2.7 | (1.4, 14) | 0.025 | 0.063 |
| (Spiro + ACEI) – (losartan + spiro) | 6.2 ± 2.2 | (0.7, 11.6) | 0.031 | 0.028 |
| Ventricular ectopics | ||||
| Baseline – losartan | 674 ± 326 | (–98, 1447) | 0.078 | 0.025 |
| Baseline – (spiro + ACEI) | 444 ± 362 | (–413, 1302) | 0.26 | 0.093 |
| Baseline – (losartan + spiro) | 725 ± 313 | (–14, 1466) | 0.053 | 0.017 |
| Losartan – (spiro + ACEI) | –230 ± 179 | (–655, 195) | 0.24 | 0.4 |
| Losartan – (losartan + spiro) | 51 ± 56 | (–82, 182) | 0.39 | 0.12 |
| (Spiro + ACEI) – (losartan + spiro) | 281 ± 172 | (–127, 690) | 0.14 | 0.23 |
Spiro: spironolactone, ACEI: angiotensin converting enzyme inhibitor.